What to expect from targeted radioisotope therapy for prostate cancer

The treatment is considered only when scans show that prostate cancer cells carry the marker recognised by the medicine. The team reviews blood counts, kidney function, medicines and previous cancer treatments. A radioactive substance is attached to a targeting carrier and given through a vein; it then releases radiation near cells carrying that marker.

You may receive fluids and other medicines around the infusion. Radiation levels and your condition are checked before discharge or during a planned stay. Commonly discussed effects include tiredness, nausea, dry mouth, changes in blood counts and kidney-related concerns.

Bring an up-to-date medicine list and mention allergies, kidney disease, urinary symptoms and pregnancy concerns affecting a partner or household. Follow instructions for fluids, toileting, hygiene and close contact. Keep appointments for blood tests and scans, and report side effects rather than stopping prescribed medicines yourself.

Call the oncology team for fever, repeated vomiting, inability to drink, much less urine, new unusual bruising or bleeding, or worsening mouth dryness that affects eating and drinking. Seek urgent help for collapse, severe breathing difficulty, severe allergic symptoms or uncontrolled bleeding. The treating unit’s radiation-safety advice takes priority for your situation.

Ask which scan finding makes the therapy suitable, how kidney and blood health will be protected, how urinary symptoms will be managed, how long precautions continue, and when response will be checked. Ask whether current hormone treatment or other medicines should continue.